Biotest Balance Sheet Health
Financial Health criteria checks 2/6
Biotest has a total shareholder equity of €527.5M and total debt of €613.9M, which brings its debt-to-equity ratio to 116.4%. Its total assets and total liabilities are €1.3B and €819.2M respectively. Biotest's EBIT is €70.0M making its interest coverage ratio 2.2. It has cash and short-term investments of €24.7M.
Key information
116.4%
Debt to equity ratio
€613.90m
Debt
| Interest coverage ratio | 2.2x |
| Cash | €24.70m |
| Equity | €527.50m |
| Total liabilities | €819.20m |
| Total assets | €1.35b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BIO3's short term assets (€704.5M) exceed its short term liabilities (€277.1M).
Long Term Liabilities: BIO3's short term assets (€704.5M) exceed its long term liabilities (€542.1M).
Debt to Equity History and Analysis
Debt Level: BIO3's net debt to equity ratio (111.7%) is considered high.
Reducing Debt: BIO3's debt to equity ratio has increased from 73.4% to 116.4% over the past 5 years.
Debt Coverage: BIO3's debt is not well covered by operating cash flow (14.6%).
Interest Coverage: BIO3's interest payments on its debt are not well covered by EBIT (2.2x coverage).